

Goat Anti-ITCH / AIF4 Antibody
Peptide-affinity purified goat antibody
Catalog # AF1573a**Specification**

Goat Anti-ITCH / AIF4 Antibody - Product Information

Application	WB, E
Primary Accession	O96J02
Other Accession	NP_113671 , 83737 , 16396 (mouse) , 311567 (rat)
Reactivity	Human
Predicted	Mouse, Rat, Dog
Host	Goat
Clonality	Polyclonal
Concentration	100ug/200ul
Isotype	IgG
Calculated MW	102803

Goat Anti-ITCH / AIF4 Antibody - Additional Information**Gene ID** 83737**Other Names**

E3 ubiquitin-protein ligase Itchy homolog, Itch, 6.3.2.-, Atrophin-1-interacting protein 4, AIP4, NFE2-associated polypeptide 1, NAPP1, ITCH

Dilution

WB~~1:1000

E~~N/A

Format

0.5 mg IgG/ml in Tris saline (20mM Tris pH7.3, 150mM NaCl), 0.02% sodium azide, with 0.5% bovine serum albumin

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

Goat Anti-ITCH / AIF4 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Goat Anti-ITCH / AIF4 Antibody - Protein Information**Name** ITCH**Function**

Acts as an E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates (PubMed:[>11046148, PubMed:\[>14602072, PubMed:\\[>15051726, PubMed:\\\[>16387660, PubMed:\\\\[>17028573, PubMed:\\\\\[>18718448, PubMed:\\\\\\[>18718449, PubMed:\\\\\\\[>19116316, PubMed:\\\\\\\\[>19592251, PubMed:\\\\\\\\\[>19881509, PubMed:\\\\\\\\\\[>20068034, PubMed:\\\\\\\\\\\[>20392206, PubMed:\\\\\\\\\\\\[>20491914, PubMed:\\\\\\\\\\\\\[>23146885, PubMed:\\\\\\\\\\\\\\[>24790097, PubMed:\\\\\\\\\\\\\\\[>25631046\\\\\\\\\\\\\\\\). Catalyzes 'Lys-29', 'Lys-48' and 'Lys-63'-linked ubiquitin conjugation \\\\\\\\\\\\\\\\(PubMed:\\\\\\\\\\\\\\\\[>17028573, PubMed:\\\\\\\\\\\\\\\\\[>18718448, PubMed:\\\\\\\\\\\\\\\\\\[>19131965, PubMed:\\\\\\\\\\\\\\\\\\\[>19881509\\\\\\\\\\\\\\\\\\\\). Involved in the control of inflammatory signaling pathways \\\\\\\\\\\\\\\\\\\\(PubMed:\\\\\\\\\\\\\\\\\\\\[>19131965\\\\\\\\\\\\\\\\\\\\\). Essential component of a ubiquitin-editing protein complex, comprising also TNFAIP3, TAX1BP1 and RNF11, that ensures the transient nature of inflammatory signaling pathways \\\\\\\\\\\\\\\\\\\\\(PubMed:\\\\\\\\\\\\\\\\\\\\\[>19131965\\\\\\\\\\\\\\\\\\\\\\). Promotes the association of the complex after TNF stimulation \\\\\\\\\\\\\\\\\\\\\\(PubMed:\\\\\\\\\\\\\\\\\\\\\\[>19131965\\\\\\\\\\\\\\\\\\\\\\\). Once the complex is formed, TNFAIP3 deubiquitinates 'Lys-63' polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains \\\\\\\\\\\\\\\\\\\\\\\(PubMed:\\\\\\\\\\\\\\\\\\\\\\\[>19131965\\\\\\\\\\\\\\\\\\\\\\\\). This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NFkB1 \\\\\\\\\\\\\\\\\\\\\\\\(PubMed:\\\\\\\\\\\\\\\\\\\\\\\\[>19131965\\\\\\\\\\\\\\\\\\\\\\\\\). Ubiquitinates RIPK2 by 'Lys-63'-linked conjugation and influences NOD2-dependent signal transduction pathways \\\\\\\\\\\\\\\\\\\\\\\\\(PubMed:\\\\\\\\\\\\\\\\\\\\\\\\\[>19592251\\\\\\\\\\\\\\\\\\\\\\\\\\). Regulates the transcriptional activity of several transcription factors, and probably plays an important role in the regulation of immune response \\\\\\\\\\\\\\\\\\\\\\\\\\(PubMed:\\\\\\\\\\\\\\\\\\\\\\\\\\[>18718448, PubMed:\\\\\\\\\\\\\\\\\\\\\\\\\\\[>20491914\\\\\\\\\\\\\\\\\\\\\\\\\\\\). Ubiquitinates NFE2 by 'Lys-63' linkages and is implicated in the control of the development of hematopoietic lineages \\\\\\\\\\\\\\\\\\\\\\\\\\\\(PubMed:\\\\\\\\\\\\\\\\\\\\\\\\\\\\[>18718448\\\\\\\\\\\\\\\\\\\\\\\\\\\\\). Mediates JUN ubiquitination and degradation \\\\\\\\\\\\\\\\\\\\\\\\\\\\\(By similarity\\\\\\\\\\\\\\\\\\\\\\\\\\\\\). Mediates JUNB ubiquitination and degradation \\\\\\\\\\\\\\\\\\\\\\\\\\\\\(PubMed:\\\\\\\\\\\\\\\\\\\\\\\\\\\\\[>16387660\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\). Critical regulator of type 2 helper T \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\(Th2\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\) cell cytokine production by inducing JUNB ubiquitination and degradation \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\(By similarity\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\). Involved in the negative regulation of MAVS-dependent cellular antiviral responses \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\(PubMed:\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\[>19881509\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\). Ubiquitinates MAVS through 'Lys-48'-linked conjugation resulting in MAVS proteasomal degradation \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\(PubMed:\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\[>19881509\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\). Following ligand stimulation, regulates sorting of Wnt receptor FZD4 to the degradative endocytic pathway probably by modulating PI42KA activity \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\(PubMed:\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\[>23146885\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\). Ubiquitinates PI4K2A and negatively regulates its catalytic activity \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\(PubMed:\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\[>23146885\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\). Ubiquitinates\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\(http://www.uniprot.org/citations/23146885\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\(http://www.uniprot.org/citations/23146885\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\(http://www.uniprot.org/citations/19881509\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\(http://www.uniprot.org/citations/19881509\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\\\\\\\\\\\(http://www.uniprot.org/citations/16387660\\\\\\\\\\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\\\\\\\\\\(http://www.uniprot.org/citations/18718448\\\\\\\\\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\\\\\\\\\(http://www.uniprot.org/citations/20491914\\\\\\\\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\\\\\\\\(http://www.uniprot.org/citations/18718448\\\\\\\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\\\\\\\(http://www.uniprot.org/citations/19592251\\\\\\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\\\\\\(http://www.uniprot.org/citations/19131965\\\\\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\\\\\(http://www.uniprot.org/citations/19131965\\\\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\\\\(http://www.uniprot.org/citations/19131965\\\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\\\(http://www.uniprot.org/citations/19131965\\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\\(http://www.uniprot.org/citations/19131965\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\(http://www.uniprot.org/citations/19881509\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\(http://www.uniprot.org/citations/19131965\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\(http://www.uniprot.org/citations/18718448\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\(http://www.uniprot.org/citations/17028573\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\(http://www.uniprot.org/citations/25631046\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\]\\\\\\\\\\\\\\(http://www.uniprot.org/citations/24790097\\\\\\\\\\\\\\)\\\\\\\\\\\\\]\\\\\\\\\\\\\(http://www.uniprot.org/citations/23146885\\\\\\\\\\\\\)\\\\\\\\\\\\]\\\\\\\\\\\\(http://www.uniprot.org/citations/20491914\\\\\\\\\\\\)\\\\\\\\\\\]\\\\\\\\\\\(http://www.uniprot.org/citations/20392206\\\\\\\\\\\)\\\\\\\\\\]\\\\\\\\\\(http://www.uniprot.org/citations/20068034\\\\\\\\\\)\\\\\\\\\]\\\\\\\\\(http://www.uniprot.org/citations/19881509\\\\\\\\\)\\\\\\\\]\\\\\\\\(http://www.uniprot.org/citations/19592251\\\\\\\\)\\\\\\\]\\\\\\\(http://www.uniprot.org/citations/19116316\\\\\\\)\\\\\\]\\\\\\(http://www.uniprot.org/citations/18718449\\\\\\)\\\\\]\\\\\(http://www.uniprot.org/citations/18718448\\\\\)\\\\]\\\\(http://www.uniprot.org/citations/17028573\\\\)\\\]\\\(http://www.uniprot.org/citations/16387660\\\)\\]\\(http://www.uniprot.org/citations/15051726\\)\]\(http://www.uniprot.org/citations/14602072\)](http://www.uniprot.org/citations/11046148)

chemokine receptor CXCR4 and regulates sorting of CXCR4 to the degradative endocytic pathway following ligand stimulation by ubiquitinating endosomal sorting complex required for transport ESCRT-0 components HGS and STAM (PubMed:14602072, PubMed:23146885, PubMed:34927784). Targets DTX1 for lysosomal degradation and controls NOTCH1 degradation, in the absence of ligand, through 'Lys-29'-linked polyubiquitination (PubMed:17028573, PubMed:18628966, PubMed:23886940). Ubiquitinates SNX9 (PubMed:20491914). Ubiquitinates MAP3K7 through 'Lys-48'-linked conjugation (By similarity). Together with UBR5, involved in the regulation of apoptosis and reactive oxygen species levels through the ubiquitination and proteasomal degradation of TXNIP: catalyzes 'Lys-48'-'Lys-63'-branched ubiquitination of TXNIP (PubMed:20068034, PubMed:29378950). ITCH synthesizes 'Lys-63'-linked chains, while UBR5 is branching multiple 'Lys-48'-linked chains of substrate initially modified (PubMed:29378950). Mediates the antiapoptotic activity of epidermal growth factor through the ubiquitination and proteasomal degradation of p15 BID (PubMed:20392206). Ubiquitinates BRAT1 and this ubiquitination is enhanced in the presence of NDFIP1 (PubMed:25631046). Inhibits the replication of influenza A virus (IAV) via ubiquitination of IAV matrix protein 1 (M1) through 'Lys-48'-linked conjugation resulting in M1 proteasomal degradation (PubMed:30328013). Ubiquitinates NEDD9/HEF1, resulting in proteasomal degradation of NEDD9/HEF1 (PubMed:15051726).

Cellular Location

Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasm. Nucleus Early endosome membrane; Peripheral membrane protein; Cytoplasmic side. Endosome membrane; Peripheral membrane protein; Cytoplasmic side. Note=May be recruited to exosomes by NDFIP1 (PubMed:18819914). Localizes to plasma membrane upon CXCL12 stimulation where it co-localizes with CXCL4 (PubMed:14602072) Localization to early endosomes is increased upon CXCL12 stimulation where it co-localizes with DTX3L and CXCL4 (PubMed:24790097)

Tissue Location

Widely expressed.

Goat Anti-ITCH / AIF4 Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Goat Anti-ITCH / AIF4 Antibody - Images



AF1573a (0.1 µg/ml) staining of Human Brain (Frontal Cortex) lysate (35 µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

Goat Anti-ITCH / AIF4 Antibody - Background

Atrophin-1 contains a polyglutamine repeat, expansion of which is responsible for dentatorubral and pallidoluysian atrophy. The protein encoded by this gene interacts with atrophin-1. This encoded protein is a closely related member of the NEDD4-like protein family. This family of proteins are E3 ubiquitin-ligase molecules and regulate key trafficking decisions, including targeting of proteins to proteosomes or lysosomes. This encoded protein contains four tandem WW domains and a HECT (homologous to the E6-associated protein carboxyl terminus) domain. It can act as a transcriptional corepressor of p45/NFE2 and may participate in the regulation of immune responses by modifying Notch-mediated signaling. It is highly similar to the mouse Itch protein, which has been implicated in the regulation and differentiation of erythroid and lymphoid cells.

Goat Anti-ITCH / AIF4 Antibody - References

The E3 ubiquitin ligase Itch regulates sorting nexin 9 through an unconventional substrate recognition domain. Baumann C, et al. FEBS J, 2010 Jul. PMID 20491914.
Cbl-b and itch: key regulators of peripheral T-cell tolerance. Venuprasad K. Cancer Res, 2010 Apr 15. PMID 20395198.
Human ITCH E3 ubiquitin ligase deficiency causes syndromic multisystem autoimmune disease. Lohr NJ, et al. Am J Hum Genet, 2010 Mar 12. PMID 20170897.
Inducible regulatory T cells (iTregs) from recent-onset type 1 diabetes subjects show increased in vitro suppression and higher ITCH levels compared with controls. Glisic S, et al. Cell Tissue Res, 2010 Mar. PMID 20143240.
The ubiquitin ligase itch regulates apoptosis by targeting thioredoxin-interacting protein for ubiquitin-dependent degradation. Zhang P, et al. J Biol Chem, 2010 Mar 19. PMID 20068034.